In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, PDS Biotechnology Corporation (NASDAQ: PDSB) closed at $4.02 up 6.49% from its previous closing price of $3.78. In other words, the price has increased by $6.49 from its previous closing price. On the day, 1.82 million shares were traded. PDSB stock price reached its highest trading level at $4.3599 during the session, while it also had its lowest trading level at $3.56.
Ratios:
For a deeper understanding of PDS Biotechnology Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.33 and its Current Ratio is at 4.33. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on November 01, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On June 28, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
H.C. Wainwright Upgraded its Neutral to Buy on November 10, 2020, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PDSB now has a Market Capitalization of 147450784 and an Enterprise Value of 105755360.
Stock Price History:
The Beta on a monthly basis for PDSB is 1.87, which has changed by -0.44809943 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, PDSB has reached a high of $10.27, while it has fallen to a 52-week low of $2.59. The 50-Day Moving Average of the stock is -3.70%, while the 200-Day Moving Average is calculated to be -18.63%.
Shares Statistics:
For the past three months, PDSB has traded an average of 911.25K shares per day and 482710 over the past ten days. A total of 36.68M shares are outstanding, with a floating share count of 34.89M. Insiders hold about 4.89% of the company’s shares, while institutions hold 22.12% stake in the company. Shares short for PDSB as of 1713139200 were 7144898 with a Short Ratio of 7.84, compared to 1710460800 on 5507120. Therefore, it implies a Short% of Shares Outstanding of 7144898 and a Short% of Float of 20.39.
Earnings Estimates
The stock of PDS Biotechnology Corporation (PDSB) is currently drawing attention from 6.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.37 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.45, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.28 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.11 and -$1.75 for the fiscal current year, implying an average EPS of -$1.48. EPS for the following year is -$1.61, with 5.0 analysts recommending between -$1.3 and -$1.97.
